More data for HMA + VEN + menin inhibitor in R/R AML (this time ASTX727 + VEN + revumenib for KMT2Ar, NPM1, or NUP98r)
ascopubs.org/doi/10.1200/...
Early-phase experience of Aza + Ven + Zifto in R/R NPM1m AML is out!
ashpublications.org/blood/articl...
check out the NCCN AML insights article focused on MRD!
pubmed.ncbi.nlm.nih.gov/42297017/
a promising early-phase study of HMA + VEN + NAV in advanced myeloid malignancies including accelerated/blast-phase MPNs
aacrjournals.org/clincancerre...
Proud of one of our amazing IM residents Dr Apoorva Ravichandran for presenting our experience using cytarabine-mitoxantrone-venetoclax for patients with R/R AML!
www.asco.org/abstracts-pr...
the Phase III SENTRY study of Rux +/- selinexor in JAK inhibitor naive MF is out!
-higher SVR35 with combo but no difference in symptom improvement
-separation of survival curves but follow-up is still short
ascopubs.org/doi/10.1200/...
happy to contribute to this effort looking at outcomes in patients with hairy cell leukemia!
pubmed.ncbi.nlm.nih.gov/42281276/
check out our video summarizing @ascocancer.bsky.social abstracts we are excited about in AML, ALL, and BPDCN!
www.vumedi.com/video/asco-a...
exciting to see PVEK as a new approved option for BPDCN!
www.fda.gov/drugs/resour...
a promising prospective study of Ven + pediatric inspired regimen in pts with newly diagnosed ALL aged 14-60!
ashpublications.org/blood/articl...
